Library Diversity
Library Diversity
Libraries Designed to Produce Drugs, Not Just Hits
Diversity is not just about clone count. It is about the quality of the sequence space being explored, and whether the clones that emerge are fit for clinical development from day one. FairJourney Bio's proprietary library portfolio is built on that principle.
Libraries Designed to Produce Drugs, Not Just Hits
Diversity is not just about clone count. It is about the quality of the sequence space being explored, and whether the clones that emerge are fit for clinical development from day one. FairJourney Bio's proprietary library portfolio is built on that principle.
Libraries Designed to Produce Drugs, Not Just Hits
Diversity is not just about clone count. It is about the quality of the sequence space being explored, and whether the clones that emerge are fit for clinical development from day one. FairJourney Bio's proprietary library portfolio is built on that principle.
Libraries Built for the Clinic
Exclusive to FairJourney Bio
Proprietary Libraries
Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.
Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.
Libraries Built for the Clinic
Exclusive to FairJourney Bio
Proprietary Libraries
Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.
Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.
Libraries Built for the Clinic
Exclusive to FairJourney Bio
Proprietary Libraries
Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.
Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.
Cosmic Library™
FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.
Architecture
Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells
Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility
25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks
100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity
What this means for your programme
Verified developability from the first round of selection
Optimised for low immunogenicity — fully human, germline frameworks
Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access
In practice: SIRPα
Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.
Cosmic Library™
FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.
Architecture
Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells
Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility
25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks
100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity
What this means for your programme
Verified developability from the first round of selection
Optimised for low immunogenicity — fully human, germline frameworks
Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access
In practice: SIRPα
Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.
Cosmic Library™
FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.
Architecture
Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells
Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility
25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks
100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity
What this means for your programme
Verified developability from the first round of selection
Optimised for low immunogenicity — fully human, germline frameworks
Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access
In practice: SIRPα
Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.
SuperHuman 2.0™
76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.
CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment
~100 donor immune repertoires combined
Highest-frequency VH paratope = 0.03% of library — truly unique sequence space
CDRH3 sequences average 9.7 amino acids apart
Thermostability, aggregation resistance, and low immunogenicity built in
5 SuperHuman-derived antibodies currently in clinical trials
SuperHuman 2.0™
76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.
CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment
~100 donor immune repertoires combined
Highest-frequency VH paratope = 0.03% of library — truly unique sequence space
CDRH3 sequences average 9.7 amino acids apart
Thermostability, aggregation resistance, and low immunogenicity built in
5 SuperHuman-derived antibodies currently in clinical trials
SuperHuman 2.0™
76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.
CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment
~100 donor immune repertoires combined
Highest-frequency VH paratope = 0.03% of library — truly unique sequence space
CDRH3 sequences average 9.7 amino acids apart
Thermostability, aggregation resistance, and low immunogenicity built in
5 SuperHuman-derived antibodies currently in clinical trials
Explorer Platform
Fully human ScFv, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.
*Early access Q1 2027
Explorer Platform
Fully human ScFv, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.
*Early access Q1 2027
Explorer Platform
Fully human ScFv, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.
*Early access Q1 2027
Full Framework Libraries
The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.
Full Framework Libraries
The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.
Full Framework Libraries
The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.
Hit Rates Across Target Classes
Immune checkpoint (soluble): 93%
Virus-associated antigen: 77%
Tumour-associated antigen: 74%
Receptor tyrosine kinase: 58–79% (across library formats)
Transmembrane single-pass Type I: 77%
Hit Rates Across Target Classes
Immune checkpoint (soluble): 93%
Virus-associated antigen: 77%
Tumour-associated antigen: 74%
Receptor tyrosine kinase: 58–79% (across library formats)
Transmembrane single-pass Type I: 77%
Hit Rates Across Target Classes
Immune checkpoint (soluble): 93%
Virus-associated antigen: 77%
Tumour-associated antigen: 74%
Receptor tyrosine kinase: 58–79% (across library formats)
Transmembrane single-pass Type I: 77%
Fullspectrum Characterization
fullspectrum-characterization
0
AnyFormat Manufacturing
anyformat-manufacturing
0
DeepDesign Engineering
deepdesign-engineering
0
FunctionInsight Assays
functioninsight-assays
0
B-Cell Navigator
b-cell-navigator
0
Solutions
solutions
1
Platforms & Technologies
platforms-technologies
0
Why FJBio
why-fjbio
0
Events & Resources
events-resources
0
Company
company
0
About
about
0
Antibody Discovery
antibody-discovery
0
Protein Production
protein-production
0
AtomicLevel Cryo-EM
atomic-level-cryo-em
0
FastTrack IND
fasttrack-ind
0
Biologistics
biologistics
0
Leadership
leadership
0
Careers
careers
0
News & Insights
news-insights
0
Case Studies
case-studies
0
Fact Sheets
fact-sheets
0
CellCraft Solutions
cellcraft-solutions
0
Cryo-EM
cryo-em
0
Display Platforms
display-platforms
0
Events
events
0
Library Diversity
library-diversity
0
MultiPath Discovery
multipath-discovery
0
Publications & Posters
publications-posters
0
Resources
resources
0
Screening | Analytics | Data Engines
screening-analytics-data-engines
0
Single B-Cell Screening
single-b-cell-screening
0
The Antibody Series Conference
the-antibody-series-conference
0
Tumbler™
tumbler
0
Webinars
webinars
0
White papers
whitepapers
0
Contact Us
contact-us
0